Biomea Fusion Inc. (BMEA), a clinical-stage biopharmaceutical company, expects to present data from its COVALENT-103 trial on December 9, 2024.
COVALENT-103 is a Phase I trial evaluating the company's drug candidate BMF-500 in adult patients with relapsed or refractory acute leukemia with FMS-like tyrosine kinase 3 (FLT3) wild-type and FLT3 mutations.
FLT3 is the most frequently mutated gene in AML, affecting up to 37% of newly diagnosed AML patients.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.